Long intergenic non‑protein coding RNA 152 promotes multiple myeloma progression by negatively regulating microRNA‑497
Authors: Tianhua Yu
Xuanhe Zhang
Lan Men
Haiying Nie
Zhihua Xu
Journal: Oncology Reports (2018)
Discipline: CLINICAL MEDICINE
Keywords: LINC00152; multiple myeloma; oncogenic effect; miR-497; cell proliferation
Affiliations: Department of Blood Transfusion, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China., Department of The 3rd Neurology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China., College of Agricultural Science, Shihezi University, Shihezi, Xinjiang 832003, P.R. China., Department of Gastrointestinal Medicine, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China., Department of Vascular Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China.

Abstract:  Long intergenic non‑protein coding RNA 152 (LINC00152, also known as cytoskeleton regulator RNA) is reportedly involved in the development and progression of various types of human malignancy. However, the functional role of LINC00152 in multiple myeloma (MM) and the underlying molecular mechanisms have remained elusive. The present study aimed to investigate the role of LINC00152 in the genesis of MM and the potential molecular mechanisms. It was identified that the expression of LINC00152 was significantly upregulated in plasma cells from patients with MM vs. healthy subjects, and that a high expression of LINC00152 was correlated with a shorter overall survival in patients with MM. Functional assays demonstrated that knockdown of LINC00152 by transfecting MM cells with LINC00152‑specific short hairpin RNA expression plasmids significantly inhibited cell proliferation by inducing cell cycle arrest at the G0/G1 phase. Furthermore, knockdown of LINC00152 promoted caspase‑3/9 activity and apoptosis in MM cells. In addition, knockdown of LINC00152 significantly attenuated tumor growth in mice bearing a myeloma xenograft. A luciferase reporter assay indicated that microRNA (miR)‑497 is a direct target of LINC00152, and its expression levels were inversely correlated with those of LINC00152 in MM tissues. Furthermore, repression of miR‑497 partly abrogated the inhibitory effects of LINC00152 knockdown on MM cells. Collectively, the results indicated that LINC00152 has an oncogenic effect in MM by targeting miR‑497, and may be a novel diagnostic marker and therapeutic target for MM. 

Retracted: Yes

PubPeer comments:
 Fig 6B.  Images ... of the excised tumors . ![file] Could the authors comment on the appearance of many of the same tumors in Fig 6B of [Li et al (2018)] ? ![file] , 
 Retracted [3 December 2021] . ---------------------- Following the publication of this paper, an interested reader drew the authors attention to the fact that several of the tumour images shown in Fig. 6B were strikingly similar to images that had appeared in another paper by different authors published at around the same time. The authors also admitted that the in vivo experiments reported in this study had been performed by a third party. Consequently, owing to a lack of confidence in the presented data, the authors requested that this paper be retracted from the Journal. The Editor was in agreement that the paper should be retracted. All authors agree with the retraction of this article, and the Editor apologizes to the readership for any inconvenience caused. ,